About DECOY THERAPEUTICS INC
Decoy Therapeutics is a biotechnology company developing a new category of antivirals called Designable Multi-Antivirals (D-MAVs), engineered to target shared viral mechanisms across multiple viruses. The company utilizes its proprietary peptide conjugate platform, IMP³ACT, which integrates AI-enabled design with rapid synthesis and manufacturing.
Development of Designable Multi-Antivirals (D-MAVs) targeting shared viral mechanismsUtilization of AI-enabled design and rapid synthesis through the IMP³ACT platformCreation of self-administered nasal spray antivirals for prophylactic and therapeutic useFocus on respiratory viruses, including coronaviruses, flu, and RSV
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to DECOY THERAPEUTICS INC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.